Introduction {#sec0005}
============

Since December2019, a novel coronavirus has broken out in Wuhan, and spread rapidly worldwide. On February 11, 2020, the World Health Organization (WHO) officially named this novel coronavirus pneumonia as Coronavirus Disease 2019 (COVID-19), whereas the International Committee on Taxonomy of Viruses has named it as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). On 11 March, WHO declared that COVID-19 should be characterized as a pandemic. Because of the highly contagious nature of SARS-CoV-2, the entire population was generally susceptible, including young children. Data from China showed young children were vulnerable to SARS-CoV-2 infection ([@bib0020]). In addition, WHO estimated that more than 2 million children under 5 years of age die from pneumonia, accounting for almost one in five under-5 deaths worldwide in 2004 ([@bib0065]). Pneumonia was the leading infectious cause of death in children younger than 5 years ([@bib0065]). Therefore, close attention should be paid to children with pneumonia less than 5 years old during the COVID-19 pandemic.

Influenza viruses have precipitated pandemics several times over the past 100 years, specifically in 1918, 1957, 1968 and 2009. Influenza A was a common cause of pneumonia in young children ([@bib0040]). Recently, Kong et al. retrospectively investigated the presence of SARS-CoV-2 among local patients with influenza like illness (ILI) from 6 October 2019 to 21 January 2020 and found SARS-CoV-2 RNA was detected in nine ILI patient specimens ([@bib0045]). In addition, ILI data for the 2019-2020 winter was significantly higher in comparison to previous years regarding children, suggesting that it was necessary to distinguish the difference between influenza A and COVID-19 pneumonia in young children. Therefore, the aim of this study was to compare the different clinical presentations between patients infected with COVID-19 pneumonia versus influenza A pneumonia, to provide some recommendations for their differential diagnosis.

Methods {#sec0010}
=======

Study design and participants {#sec0015}
-----------------------------

Subjects of the study were consecutive children with either confirmed COVID-19 pneumonia (admitted between 28 January and 11 March 2020) or influenza A pneumonia (admitted between 14 December 2019 and 30 February 2020) in Wuhan Children\'s hospital. The study was approved by the Research Ethics Board of Wuhan Children\'s Hospital (No. 2020003). Consent of the patients' legal guardians was obtained.

Definitions {#sec0020}
-----------

Children were included in the study if they had evidence consistent with pneumonia as assessed by means of chest radiography or CT within 72 h before or after admission. The virus nucleic acid detection kit confirmed COVID-19 patients through detecting the RNA of SARS-CoV-2 in throat swab samples based on the manufacturer\'s protocol (Shanghai BioGerm Medical Biotechnology Co., Ltd.). Influenza A was detected by direct immunofluorescence assay. The diagnostic criteria for severe pneumonia caused by SARS-CoV-2 and influenza A conform to guidelines ([@bib0005], [@bib0030]).

Data collection {#sec0025}
---------------

A COVID-19 or influenza A case report form was designed to document primary data regarding demographic, clinical and laboratory characteristics from electronic medical records. The following information was extracted from each patient: gender, age, medical history, chief complaints, laboratory findings and computed tomography (CT) imaging on admission.

Statistical analysis {#sec0030}
--------------------

Categorical data were described as percentages, and continuous data as median with standard deviation (SD). Nonparametric comparative test for continuous data and *χ* ^2^ test for categorical data were used to compare variables between groups. The statistical analyses were performed using SPSS Statistics version 25.0 software. *P*  \< 0.05 was considered statistically significant.

Results {#sec0035}
=======

Baseline characteristics of COVID-19 and influenza A patients {#sec0040}
-------------------------------------------------------------

A total of 57 COVID-19 patients and 59 influenza A patients were included ([Table 1](#tbl0005){ref-type="table"} ). No significant differences were found in the median age between COVID-19 patients and influenza A patients (18.7 months vs. 21.8 months, *P*  = 0.121). The proportion of males to females was also not significantly different between the two groups (61.4% vs. 66.1%, *P*  = 0.599). The most common symptoms and signs were cough (84.5%), fever (69.8%) and gastrointestinal symptoms (25%), whereas dyspnea (6.0%) and convulsions (3.4%) were less common. Moreover, the proportions of cough (70.2%), fever (54.4%) and gastrointestinal symptoms (14.1%) in COVID-19 patients were lower than those of influenza A patients (98.3%, *P*  \< 0.001; 84.7%, *P*  \< 0.001; and 35.6%, *P*  = 0.007; respectively). Additionally, the highest body temperature of influenza A patients was also significantly higher than that of COVID-19 patients (38.5 °C vs. 39.3 °C, *P*  \< 0.001). The proportion of severe pneumonia in COVID-19 patients was also lower than that in patients infected with influenza A (3.5% vs. 18.6%, *P*  = 0.016) ([Table 1](#tbl0005){ref-type="table"}).Table 1Characteristics of patients with COVID-19 or Influenza A.Table 1VariableNo. (%) or median ± SD*P* valueTotal (*n* = 116)COVID-19 (*n* = 57)Influenza A (*n* = 59)Male74 (63.8)35 (61.4)39 (66.1)0.599Age (months)20.2 ± 16.718.7 ± 16.721.8 ± 16.70.121Severe pneumonia13 (11.2)2 (3.5)11 (18.6)0.016Symptoms and signs Fever81 (69.8)31 (54.4)50 (84.7)*\<0.001* Highest temperature (°C)38.9 ± 0.738.5 ± 0.739.3 ± 0.6*\<0.001* Cough98 (84.5)40 (70.2)58 (98.3)*\<0.001* Dyspnea7 (6.0)2 (3.5)5 (8.5)0.439 Gastrointestinal symptoms29 (25)8 (14.1)21 (35.6)0.007 Convulsions4 (3.4)1 (1.7)3 (5.1)0.619Hospitalized treatment Oxygen inhalation8 (6.9)1 (1.7)7 (11.8)0.061 ICU6 (5.2)2 (3.5)4 (6.7)0.679[^2]

Laboratory and imaging findings between COVID-19 and influenza A patients {#sec0045}
-------------------------------------------------------------------------

For blood inflammatory indictors, lower levels of C-reactive protein (CRP) and procalcitonin (PCT) were observed in COVID-19 patients than in influenza A patients (3.7 vs. 15.1 mg/L, *P*  = 0.001; 0.09 vs. 0.68 ng/ml, *P*  \< 0.001). For routine blood tests, COVID-19 patients showed significantly lower levels of leukocytes and neutrophils, while lymphocyte levels were significantly higher compared with influenza A patients (7.87 vs. 9.89 × 10^9^  L^--1^, *P*  = 0.027; 2.43 vs. 5.16 × 10^9^  L^--1^, *P*  \< 0.001; 4.58 vs. 3.56 × 10^9^  L^--1^; *P*  = 0.006). For biochemistry testing, no significant differences were found in the alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin (ALB), bilirubin, blood urea nitrogen (BUN) and blood creatinine between the two groups of patients. However, lower levels of [d]{.smallcaps}-dimer and prothrombin time (PT) and potassium ion were found in COVID-19 patients than influenza A patients (0.34 vs. 1.94, *P*  \< 0.001; 10.8 vs. 11.2 mm/h, *P*  = 0.014; 5.14 vs. 7.07 mmol/L, *P*  = 0.001) ([Table 2](#tbl0010){ref-type="table"} ).Table 2Laboratory findings of COVID-19 and Influenza A patients.Table 2VariableNo. (%) or median ± SD*P* valueTotal (*n* = 116)COVID-19 (*n* = 57)Influenza A (*n* = 59)Blood routine test Leukocytes (×10^9^ L^--1^)8.88 ± 4.077.87 ± 2.879.89 ± 4.840.027 Neutrophils (×10^9^ L^--1^)3.81 ± 3.692.43 ± 1.925.16 ± 4.46\<*0.001* Lymphocytes (×10^9^ L^--1^)4.06 ± 2.094.58 ± 2.063.56 ± 2.01*0.006* Platelets (×10^9^ L^--1^)304 ± 110298 ± 107311 ± 1130.455 Hemoglobin((g/L))117 ± 11117 ± 11117 ± 120.932Coagulation function PT (s)10.9 ± 0.810.8 ± 0.711.2 ± 0.80.014 APTT (s)33.6 ± 5.433.4 ± 5.234.1 ± 5.90.650 [d]{.smallcaps}-Dimer (ng/ml)0.8 ± 1.70.34 ± 0.291.94 ± 2.88\<*0.001*Inflammatory indictors CRP (mg/dl)9.5 ± 24.13.7 ± 6.8515.1 ± 32.20.001 PCT (ng/ml)0.41 ± 1.350.09 ± 0.090.68 ± 1.82\<*0.001*Biochemical test ALT (U/L)31 ± 5736 ± 7826 ± 250.595 AST (U/L)54 ± 6457 ± 8650 ± 300.591 TIBL (umol/L)7.44 ± 4.537.35 ± 4.587.51 ± 4.520.799 ALB (g/L)43.1 ± 5.542.7 ± 6.943.5 ± 3.60.964 CK (U/L)138 ± 106147 ± 89130 ± 1210.042 LDH (U/L)338 ± 128319 ± 92357 ± 1540.340 CK-MB (U/L)42 ± 3238 ± 2046 ± 411.000 Creatinine (umol/L)28.6 ± 29.926.5 ± 24.730.6 ± 34.20.939 BUN (mmol/L)3.3 ± 1.73.48 ± 2.243.24 ± 1.150.122[^3]

In terms of CT imaging, ground-glass opacification in chest CT was more common in COVID-19 patients than in influenza A patients (42.1% vs. 15%, *P*  = 0.032). In contrast, consolidation was more common in influenza A patients (25%) than that in COVID-19 patients (5.2%, *P*  = 0.025) ([Figure 1](#fig0005){ref-type="fig"} and [Table 3](#tbl0015){ref-type="table"} ).Figure 1**Imaging characteristics of chest CT from COVID-19 and influenza A patients**. (a) A 1-year-old boy with COVID-19 exhibited ground-glass opacity mixed consolidation in both lungs. (b) A 7-month-old girl with COVID-19 exhibited ground-glass opacities in left lung. (c) A 1-month-old boy with COVID-19 exhibited consolidation in right lung. (d) A 1-year-old boy with influenza A exhibited exudation and consolidation distributed diffusely in both lungs. (e) A 2-year-old girl with influenza A exhibited consolidation in right lung. (f) A 2-year-old boy with influenza A exhibited consolidation in left lung and ground-glass opacity in right lung.Figure 1Table 3CT Imaging findings of patients with COVID-19 or H1N1 at presentationTable 3VariableNo. (%)*P* valueTotal (*n* = 77)COVID-19 (*n* = 57)H1N1 (*n* = 20)Patterns of the lesion Ground glass opacification24 (20.7)24 (42.1)3 (15)0.032 Consolidation8 (6.9)3 (5.2)5 (25)0.025[^4]

Discussion {#sec0050}
==========

Since December 2019, an outbreak of coronavirus disease 2019 (COVID-19) has spread globally. The outbreak of COVID-19 began in December 2019, which also corresponded with the flu season in China ([@bib0075]). It is important to differentiate these two respiratory infectious diseases via early clinical presentation in consideration of their different therapies, prognoses, and protective measures. In this study, we first compared the different clinical courses of pneumonia caused by SARS-CoV-2 and influenza A virus. We found that COVID-19 patients were mild in clinical symptoms and laboratory examinations in children under 5 years. Additionally, imaging results more commonly presented as ground-glass opacity in COVID-19 patients.

As we found before, cough and fever were common symptoms in COVID-19 ([@bib0050]), which is similar with influenza A. Our present study revealed that COVID-19 manifested as mild; severe pneumonia was less than influenza A patients. Some COVID-19 patients only presented as fever or cough. Meanwhile, influenza A patients were more likely to have fever with higher temperature. Gastrointestinal symptoms were common in patients with COVID-19 ([@bib0015]), however, they were less than compared with influenza A. Convulsions could be found in both patients, but the reason was different, as only one in COVID-19 was secondary to pneumonia and three in influenza A were confirmed as febrile convulsion.

Lymphopenia and increase in [d]{.smallcaps}-dimer were common laboratory abnormalities in COVID-19 adults ([@bib0035], [@bib0060]) and were proven as a caution for severity in COVID-19 ([@bib0055], [@bib0070], [@bib0080]). In our study, lymphocyte count and [d]{.smallcaps}-dimer were lower in influenza A patients than in COVID-19, which could further prove that COVID-19 is milder than influenza A. Similarly, CRP (C-reactive protein) and PCT (procalcitonin), which was the severity index of pneumonia, were lower in COVID-19 than influenza A.

In our study, we found that ground-glass opacity was more common in COVID-19 patients than in influenza A patients, whereas consolidation was more frequent in influenza A patients, which was consistent with previous studies. The radiological findings of children with COVID-19 pneumonia from our team and other studies showed that ground-glass opacities were the most common pattern of abnormalities in chest CT ([@bib0010]). Additionally, studies on influenza A-associated pneumonia showed that consolidation was common on CT ([@bib0025]). Therefore, these differential pathological changes may contribute to distinguish imaging characteristics during clinical assessments.

There were some limitations of our present study. First, this was a retrospective study that included data from a single-center cohort. We hope for a prospective cohort and multi-center study. Second, influenza A was diagnosed by direct immunofluorescence assay and failed to be typed.

In conclusion, COVID-19 cases were mild not only in clinical symptoms but also in laboratory examination results which included lymphocyte, CRP, PCT, and [d]{.smallcaps}-dimer in the children under 5 years. Additionally, imaging results more commonly presented as ground-glass opacity in COVID-19 patients.
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